Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells

ABL tyrosine kinase inhibitor (TKI) therapy has improved the survival of patients with Philadelphia (Ph) chromosome-positive leukemia. However, ABL TKIs cannot eradicate leukemia stem cells. Therefore, new therapeutic approaches for Ph-positive leukemia are needed. Aberrant activation of phosphoinos...

Descripción completa

Detalles Bibliográficos
Autores principales: Okabe, Seiichi, Tauchi, Tetsuzo, Tanaka, Yuko, Sakuta, Juri, Ohyashiki, Kazuma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288172/
https://www.ncbi.nlm.nih.gov/pubmed/27437766
http://dx.doi.org/10.18632/oncotarget.10605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288172/
https://www.ncbi.nlm.nih.gov/pubmed/27437766
http://dx.doi.org/10.18632/oncotarget.10605

Ejemplares similares